Kyowa Hakko Kirin, Otsuka Pharmaceutical sales and marketing update

Kyowa launched once-daily, oral Onglyza saxagliptin in Japan to treat Type II diabetes. The product has a Japanese National Health Insurance (NHI) list price of ¥110.20 ($1.11) per 2.5 mg tablet and ¥166 ($1.67) per 5 mg tablet. The oral dipeptidyl peptidase-4 (DPP-4) inhibitor was approved in Japan in March. Kyowa has exclusive, Japanese rights to commercialize Onglyza under a June 2012 deal with Otsuka (see BioCentury, July 2, 2012). ...